Tu1164 Environmental Risk Factors in Inflammatory Bowel Disease in Asia-Pacific: A Population-Based Case-Control Study
Siew C. Ng,Rupert W. Leong,Yanna Ko,Corrie Studd,Ola Niewiadomski,Sally Bell,Michael A. Kamm,H.J. De Silva,Anuradhani Kasturiratne,Yasith Udara Senanayake,Choon Jin Ooi,Khoon‐Lin Ling,David E. Ong,Khean‐Lee Goh,Ida Hilmi,Qin Ouyang,Yufang Wang,Pinjin Hu,Minhu Chen,Zhirong Zeng,Kaichun Wu,Xin Wang,Bing Xia,Jin Li,Pises Pisespongsa,Sathaporn Manatsathit,Satimai Aniwan,Marcellus Simadibrata,Murdani Abdullah,Whitney Tang,Steve Tsang,Tc Wong,Hon Ho Yu,Francis K.L. Chan,Joseph J.Y. Sung
DOI: https://doi.org/10.1016/s0016-5085(14)62785-2
IF: 29.4
2014-01-01
Gastroenterology
Abstract:Introduction.In recent pilot studies, the use of a hemostatic powder showed promising results to treat gastrointestinal bleeding.However, few data exist in routine practice with this new method.Therefore, the aims of this multicenter prospective study were to determine 1) the feasibility of the application of the hemostatic powder in routine clinical practice, and 2) its effectiveness in the short and medium term in different clinical situations.Patients and methods.We performed a prospective multicenter study in 15 centers, with 27 endoscopists.All patients receiving the hemostatic powder TC-325 (Hémospray™, Cook Medical, USA) were included.The hemostatic powder was sprayed endoscopically onto the bleeding site using a catheter passed through the operative channel of the endoscope.The quantity of powder was administered at the discretion of the endoscopist based on clinical efficacy.The following parameters were analyzed: demographic characteristics, type of exteriorization (hematemesis, melena, hematochezia), hemoglobin, type of bleeding lesion, use of hemostatic powder as a first-line treatment or a rescue therapy (i.e. after failure of conventional treatment) and ease of use of the hemostatic powder as well as the main outcomes parameters, which were: firstly, the immediate efficacy defined by hemostasis achieved at the end of the endoscopic procedure, and secondly the absence of clinical recurrence eight days after the procedure.Results.Thirty nine patients (33M/11F) aged 69 ± 12 years were included in the study between March and November 2013.Patients were hospitalized for hematemesis (n = 16), melena (n = 28) or hematochezia (n = 3).Initial hypotension was noted in 11 patients.The hemoglobin level was 9 ± 2.1g/dL).At endoscopy, an active bleeding was noted in 40/44 (90.9%) cases, either pulsatile (11.4%) or oozing (88.6%).The location of bleeding was esophageal (n = 7), gastric (n = 15) or duodenal (n = 22).The bleeding lesion was identified in 37/39 (94.9%) cases.These lesions were 19 tumors (43%), 18 ulcers (41%), 5 bleeding margins following endoscopic mucosal resection (11%), 1 dilaceration of the esophagus due to rigid esophagoscopy (2,5%), 1 esophageal varices (2,5%).Application of the hemostatic powder was found to be very easy, easy, moderately easy or difficult in respectively 41.8%, 41.8%, 4.8% and 11.6% of cases.This treatment was used as a firstline treatment in 47.6% of cases and as a rescue therapy in 52.4% of cases.The immediate efficacy rate was 95.2%.No recurrence of bleeding was noted in 74.5% of cases.Conclusion.Our multicenter data obtained in routine practice conditions suggest the good feasibility and effectiveness of the hemostatic powder applied endoscopically for gastrointestinal bleeding, even after failure of conventional methods.